Myriad Genetics Inc key statistics and ratios

In fiscal 2025, Myriad Genetics Inc had return on equity of -68.5%, an operating margin of -47.0%, debt equal to 34.0% of equity and a current ratio of 2.49. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Myriad Genetics Inc: financial ratios, annual
Fiscal year	2009Jun 2009	2010Jun 2010	2011Jun 2011	2012Jun 2012	2013Jun 2013	2014Jun 2014	2015Jun 2015	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	86.7%	87.8%	88.6%	89.6%	89.5%	87.7%	81.6%	82.4%	81.2%	—	—	—	—	70.2%	68.6%	69.9%	69.9%	68.8%
Operating margin	38.7%	37.2%	39.2%	36.4%	37.2%	35.3%	18.5%	20.4%	5.7%	16.4%	0.9%	−36.3%	−27.6%	−20.7%	−34.2%	−14.7%	−47.0%	−12.2%
Net margin	25.9%	42.0%	25.0%	22.6%	24.0%	22.6%	11.0%	15.5%	2.3%	17.9%	0.5%	−31.2%	−3.9%	−16.5%	−35.0%	−15.2%	−44.4%	−14.0%
Free-cash-flow margin	23.4%	40.6%	31.6%	26.7%	26.5%	22.6%	16.1%	21.4%	13.0%	14.5%	8.8%	7.9%	0.1%	−22.3%	−14.7%	−1.0%	0.2%	1.0%
Return on equity	19.5%	30.7%	17.9%	18.7%	21.6%	24.3%	11.6%	16.7%	2.3%	15.4%	0.4%	−19.9%	−2.9%	−12.1%	−31.6%	−17.2%	−68.5%	−33.5%
Return on assets	—	25.6%	16.7%	17.2%	19.7%	21.7%	10.0%	14.2%	1.7%	11.2%	0.3%	−13.4%	−2.0%	−8.9%	−22.5%	−11.7%	−42.2%	−16.7%
Asset turnover	—	0.61	0.67	0.76	0.82	0.96	0.91	0.92	0.74	0.62	0.62	0.43	0.51	0.54	0.64	0.77	0.95	1.20
Current ratio	—	17.26	12.16	9.40	7.50	4.00	4.13	4.35	1.39	3.21	2.96	2.26	2.37	2.00	2.01	1.82	2.49	2.21
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	13.0%	1.0%	21.6%	24.7%	0.0%	0.0%	4.9%	5.8%	34.0%	41.1%
Interest cover (operating income ÷ interest)	—	—	—	—	—	—	—	—	7.3x	38.1x	0.6x	n/m	n/m	n/m	n/m	n/m	n/m	n/m
Effective tax rate	0.1%	−8.1%	36.9%	39.2%	36.9%	36.6%	40.6%	24.9%	52.5%	−10.8%	—	—	—	—	—	—	—	—
R&D as % of revenue	5.5%	6.0%	6.9%	8.6%	8.8%	8.7%	10.4%	9.4%	9.6%	9.5%	10.1%	12.1%	11.9%	12.6%	11.8%	13.5%	13.0%	13.1%
SG&A as % of revenue	42.5%	44.5%	42.2%	42.0%	41.1%	42.0%	50.6%	47.7%	57.0%	58.5%	65.4%	79.4%	77.9%	75.9%	76.1%	—	—	—
Capital spending as % of revenue	2.3%	2.2%	0.9%	1.9%	1.9%	1.8%	3.3%	0.7%	0.8%	1.1%	1.0%	1.6%	2.6%	6.7%	0.0%	0.0%	0.0%	0.0%
Free cash flow ÷ net income	90.4%	96.6%	126.1%	118.1%	110.4%	99.8%	146.1%	137.6%	575.3%	80.6%	>999%	—	—	—	—	—	—	—
Dividends and buybacks ÷ free cash flow	—	48.5%	157.8%	97.0%	90.0%	163.6%	180.7%	100.8%	31.6%	0.0%	66.6%	0.0%	0.0%	—	—	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Myriad Genetics Inc: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	70.2%	71.7%	68.5%	71.2%	69.9%	70.0%	68.7%	66.6%
Operating margin	−9.4%	−18.5%	−14.8%	−154.5%	−11.3%	−2.7%	−15.3%	−20.4%
Net margin	−10.4%	−20.2%	−0.1%	−155.1%	−13.3%	−3.8%	−17.0%	−22.7%
Free-cash-flow margin	0.3%	3.1%	−8.3%	−6.4%	10.3%	5.1%	−7.8%	−4.4%
Current ratio	1.90	1.82	1.90	1.42	2.33	2.49	2.40	2.21
Debt to equity	5.3%	5.6%	8.4%	15.3%	32.1%	32.6%	35.7%	39.7%
R&D as % of revenue	13.4%	15.3%	14.0%	12.0%	13.7%	12.2%	13.5%	13.1%
SG&A as % of revenue	65.2%	—	—	—	—	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 7 checks passed · June 30, 2026

What it owns · $639m

Short-term assets $289mLonger-term assets $350m

What it owes, and who funded it · $639m

Short-term liabilities $131mLonger-term liabilities $204mShareholders' equity $304m

Short-term assets cover short-term liabilities $289m of assets due within a year against $131m of liabilities due within a year.
Short-term assets cover long-term liabilities $289m short-term assets against $204m of longer-dated liabilities.
More cash than debt $115m of cash against $121m of debt.
Debt below 40% of shareholders' equity Debt is 40% of equity.
Debt burden no higher than five years ago Debt to equity moved from 0% to 40% over five years.
A year's operating cash flow covers at least 20% of debt $8m of operating cash flow against $121m of debt.
Operating profit covers interest at least five times over Operating income of −$99m against $16m of interest.

From Myriad Genetics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

26 /100

Weak moat

How hard Myriad Genetics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -10.5% of total assets over 10 years.
Durability 10 / 20

Operating margin has been a median -21.4%; its worst year was -50.1%.
Cash conversion 4 / 20

Free cash flow was positive in 4 of 10 years, at a median -4.0% of revenue.
Discipline 7 / 20

The diluted share count rose 23.7% over five years; stock-based pay has been a median 4.4% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IRTC vs MYGN MYGN vs OFIX ATEC vs MYGN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Myriad Genetics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Myriad Genetics Inc.